Search

CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico PURPOSE: To evaluate the effects of copaiba oil administered by different routes on survival of mices subjected to cecal ligation and puncture. METHODS: Thirty two mice were distributed into four study groups (N=8): Sham group: normal standard animals; Control group: submitted a cecal ligation and puncture (CLP); Gavage group: submitted a CLP, and treat with copaiba oil by gavage; and Subcutaneous group: submitted a CLP, and treat with copaiba oil by subcutaneous injection. After the death of the histological analysis were performed. The Kaplan-Meier curves of surviving time were realized. RESULTS: All animals that received copaiba, regardless of the route used, survived longer when compared to the control group (p0.05). CONCLUSION: Prophylactic subcutaneous administration of copaiba in mice subjected to severe sepsis by cecal ligation and puncture, resulted in a survival time higher than non-use or use of this oil by gavage. SILVEIRA, E. L. Universidade Federal do Pará

Introduction Preeclampsia (PE) is an important cause to maternal and perinatal morbimortality. The usage of acetylsalicylic acid (ASA) and Calcium (Ca) has been recommended to risk patients’ groups as preventive measures. Amongst the preeclampsia developing risk groups there are primiparous patients. However, we verified that this kind of intervention has been barely done in Sao Paulo and it seems not to be changed despite the consistent evidence to recommend its usage. Objectives Evaluate the ASA and Ca prescription frequency to primiparous patients. Methodology A comparative and retrospective study between two groups of primiparous patients was conducted. Firstly, all primiparous patients who have developed preeclampsia between January and May of 2016 and whose child-birth happened in Hospital Maternidade Vila Nova Cachoeirinha (HMEC) in Sao Paulo were identified through records evaluation and prenatal care portfolio. After that, a control group of primiparous patients who did not present any pathology during the gestation period was chosen and they were paired accordingly to their maternal age and gestational age at the child-birth. Results From that 23 primiparous pregnant woman with preeclampsia, 17.4% took ASA; 8.7% took Ca. Amongst the primiparous who did not develop preeclampsia, 2% took ASA; 12.2% took Ca and 2% took both medications (Table 1). There were no significant differences among the groups (p = 0.094). Conclusion Despite the consistent evidences for the usage of ASA and Ca, apparently the primary care in Sao Paulo city did not widely incorporate the recommendation of preventive measures to PE among high-risk patients. It is possible to assume that this behavior standard is similar among patients with other risk factors. Considering the strategic matter of prenatal care, that observation can be taken as a first step in order to enlarge this analysis and guide public policies to increase the usage of ASA and Ca in PE-risk patients. The authors thank the support FAPESP 2014.00213/7.

Introduction Pre-eclampsia (PE) is one of the biggest causes for maternal mortality in the world. Identifying risk groups and using acetylsalicylic acid (AAS) and calcium (Ca) are pointed as important measures in the attempt to reduce maternal and fetal morbidity. Aim To assess, among patients with PE, the percentage of risk factors (RF) identifiable and to verify, among them, how many have used some prevention method. Methodology it were evaluated medical records and prenatal cards of all patients that have developed PE (n = 50) between January and May 2016. Also, a targeted questionnaire was applied to identify the RF and the use of some preventive medication for PE. It were considered RF: primiparity, previous PE history, chronic arterial hypertension, pre-existent kidney disease, thrombophilias, autoimmune diseases, multiple pregnancy, PE family history, diabetes mellitus, obesity and advanced maternal age. All patients have signed a free informed consent. Results The results are presented in the attached table. The vast majority of patients with PE (90%) had some RF identifiable during prenatal and a great part (86%) presented more than one. However, it was observed a small prescription rate of AAS and/or Ca in this population. Conclusion We have observed that among patients with PE, the RF presence is considerable. We also have observed a low prescription of AAS and Ca in this population. PE is a potentially fatal pathology and the interventions in an attempt to prevent its arising are few. We have verified that despite they exist, they are not used in the routine practice. Actions for making the assisting team more conscious shall be employed, as well as disseminating the scientific knowledge in a more comprehensive form. Download : Download high-res image (512KB) Download : Download full-size image

Introduction Pre-eclampsia (PE) is a public health problem with possible fatal consequences for mother and fetus. Recent studies point that the regular consumption of chocolate and its metabolites could exert a beneficial cardiovascular effect, acting in the endothelial dysfunction and oxidative stress, important changes also observed in PE. Literature has been controversial regarding this issue but there are still many questions about the possible impact of these substances in the physiopathological process involved in PE. Aim To assess, in a convenience sample, the chocolate consumption profile in patients diagnosed with PE. Methodology A comparative and retrospective study was performed between two groups of primiparous patients. Initially were identified all patients that have developed pre-eclampsia between January and May 2016 (n = 49) whose birthing happened on Maternity Hospital Vila Nova Cachoeirinha (HMEC) at the city of Sao Paulo by means of medical records and prenatal cards. A control group (n = 48) of primiparous patients was formed that did not present pathologies during pregnancy, paired according to maternal age and birth gestational age. Through the questionnaire, it was evaluated the weekly chocolate consumption frequency in these patients. The following possibilities were considered: (a) less than once a week, (b) once a week, (c) twice a week and (d) more than 3 times a week. Results For all consumption ranges informed, meaningful differences among the groups were not detected (Table 1). Conclusion Despite some studies suggest the use of chocolate in pregnancy as a possible protective factor for PE development, the results obtained in the sample studied do not identify any correlation. However, it shall be considered the limitations of this study having in sight the sample size included and the difficulties to define accurately the quality of the food consumed. Additional studies are needed to understand the possible impact of chocolate consumption in the physiopathological process and consequential PE prevention. The authors thank the support of FAPESP 2014.00213/7.